Insilico reached the first R&D milestone using its proprietary Pharma.AI platform, triggering an undisclosed milestone ...
Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month ...
Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September ...
Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...
Approval based on phase III data showing unprecedented functional cure rates compared to standard of care ...
RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on ...
CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management ...
A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to ...
(“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of ...
China may be taking the majority of licensing deals this year but those transactions don’t tell the whole story, according to ...
Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed "This post ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results